RELIENCE INDUSTRIES LIMITED
Attn: S.R.V. Raju, Head of the Department
Product & Application Technology
Maker Chambers - IV 9th Floor
222, Nariman Point
Mumbai - 400021 INDIA

Dear Sir/Madam:

The Food and Drug Administration acknowledges receipt of the following
Drug Master File (DMF) submission:

**DMF Number Assigned:** 21727  **Date of Submission:** June 17, 2008

**DMF Type:** III

**Title of Submission:** Polypropylene (PP), Grade: H200MA as manufactured
in Jamnagar (Gujrat), India

**Holder of Submission:** Reliance Industries Limited

**Submitted by:** Reliance Industries Limited

**Agent(s):** None

All subsequent correspondence to this DMF should be identified with
the information as provided above. Submissions to the DMF should be
forwarded in duplicate.

Your DMF will be reviewed only in connection with the New Drug
Applications, Abbreviated New Drug Applications, Investigational New
Drug Applications or any DMFs it is intended to support.

The holder of the DMF is responsible for compliance with the
Regulation Title 21 Code of Federal Regulations Part 314.420 as
interpreted in “The Guideline for Drug Master Files” [HEW (FDA) 79-
3072. www.fda.gov/cder/guidance/dmf.htm. You are expected to:

- Adhere to the statement of the commitment you have provided
- Provide to the FDA by submission to the DMF in two copies:
  - Amendments to the DMF. The types of information to be
    submitted in an amendment include:
    - any change or addition to the technical information,
      adequately cross-referenced to the date(s), volume(s),
      section(s), and/or page number(s) affected.
    - any change in authorization related to specific customers
any change in holder name or ownership of the DMF or a change in the agent name or address. Such changes should be reported as separate amendments.

- an annual update of the DMF containing:
  - a list of all changes and additional information incorporated into the DMF since the previous annual report on the subject matter of the DMF. If the subject matter of the DMF is unchanged, provide a statement that the subject matter of the DMF is current. Note that the annual update is not intended for reporting changes to the DMF. Such changes should be reported as separate amendments.
  - a list of all persons authorized to make reference to the DMF, identifying by name (or code) the information that each person is authorized to incorporate and give the location of that information by date, volume, and page number. If the list is unchanged on the anniversary date, submit a statement that the list is current.
  - identification of any party whose authorization has been withdrawn

Sincerely,

Sharon L. Brownewell
Public Health Analyst
Manager of Drug Master Files
Office of Business Processing Services
Records Repository Team

CC:
Linked Applications
MF 21727

Sponsor Name
RELIANCE INDUSTRIES LTD

Drug Name
NO DRUGNAME

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SCOTT E ZEISSL
06/27/2008